SCHEMBL3840296

SCHEMBL3840296

COc1cccc(C(=O)c2ccc(Cl)nc2N)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 5/20 0.52
CDK5R1 Q15078 5/20 0.52
KDM4E B2RXH2 1/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
GSK3A P49840 1/20 0.50
GSK3B P49841 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 1/20 0.50
CYP2C8 P10632 1/20 0.50
PARP1 P09874 1/20 0.50
CCNA2 P20248 1/20 0.49
CDK2 P24941 1/20 0.49
STS P08842 2/20 0.49
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
KCNQ3 O43525 1/20 0.48
KCNQ2 O43526 1/20 0.48
CNR2 P34972 1/20 0.48
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3840933 0.83 MAPT (0.55) CDK5CDK5R1HTTPARP1CES2
SCHEMBL8569592 0.78 CDK5 (0.53) CDK5CDK5R1KDM4ETP53HTT
SCHEMBL5618019 0.78 RAB9A (0.55) CDK5CDK5R1TP53HTTSMN1; SMN2
SCHEMBL5617962 0.77 PARP1 (0.58) HTTCYP2C8PARP1STSCES2
SCHEMBL27682344 0.77 BTK (0.42) TP53HTTKCNQ3KCNQ2MAPT
SCHEMBL2702939 0.77 RAB9A (0.56) CDK5CDK5R1KDM4ETP53SMN1; SMN2
SCHEMBL7974718 0.75 CES2 (0.50) CDK5CDK5R1CYP2C8PARP1STS
SCHEMBL4267213 0.75 GAA (0.59) KDM4EHTTSMN1; SMN2CYP2C8PARP1
SCHEMBL31414638 0.74 CES2 (0.77) SMN1; SMN2CYP2C8PARP1STSCES2
SCHEMBL4823687 0.74 CES2 (0.77) SMN1; SMN2CYP2C8PARP1STSCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771420-B1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1771420-B1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
EP-1771420-A1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-11 EP disclosed
US-20060014708-A1 2,6-Diaminopyridine derivatives BARTKOVITZ DAVID J 2006-01-19 US disclosed
WO-2006005548-A1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014708-A1 2,6-Diaminopyridine derivatives CDK2, CCNA2, CDK6 CDK5 23/4885CDK5R1 35/4885KDM4E 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.